Whoa! These 3 Stocks Outmaneuvered the Dow: Allscripts Healthcare Solutions Inc (MDRX), Threshold Pharmaceuticals, Inc. (THLD)

Yet it was also noted that rivals like Tencent continued to erode the amount of time people spent on Weibo. The WeChat application has gained in popularity, forcing Sina to focus more intently on the mobile space than it had previously. Although it experienced a slowdown in active user growth on Weibo in the fourth quarter, management still expects the user base to grow now that it has reached a “critical mass.”

Carried over the threshold
It wasn’t anything so exciting as what’s going on at Allscripts that caused Threshold Pharmaceuticals to jump 11%, but analysts at Piper Jaffray are pretty stoked nonetheless about the potential of the biotech’s experimental cancer drug TH-302 that they upgraded their outlook on its stock to “overweight” from “neutral.” The move comes ahead of clinical trial data Threshold is preparing to report, and the analyst seems confident enough that he doubled his price target to $10 a share.

Threshold’s stock is up almost 15% already in 2013 following its announcement last month that it had initiated phase 3 trials for TH-302 to treat pancreatic cancer. The biotech’s leading drug candidate is being tested for several indications, but as the Fool’s Brandy Betz notes, the pancreatic cancer tests are perhaps the key for it as it is being tested alongside Gemzar, a first-in-line treatment from Eli Lilly & Co. (NYSE:LLY). TH-302 suffered a speed bump last fall when survival rates were insignificantly different from Gemzar, but it wasn’t a fatal blow because that wasn’t its primary endpoint.

The phase 3 trials it’s currently undertaking will seek out improved survival rates, so that’s what analysts will be closely monitoring. Achieving its goal will push the drug to the forefront, and with Merck KGaA paying its clinical trial bills, Threshold seems to runs little risk of running out of money. Piper Jaffray seems to believe it’s already made it there.

The article Whoa! These 3 Stocks Outmaneuvered the Dow originally appeared on Fool.com and is written by Rich Duprey.

Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends Sina.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.